Viridian Therapeutics Inc VRDN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:00 PM EDT
12.88UNCH (UNCH)
Volume
26,190
Close
12.88quote price arrow down-0.65 (-4.80%)
Volume
775,419
52 week range
10.93 - 28.35
Loading...
  • Open13.50
  • Day High13.55
  • Day Low12.73
  • Prev Close13.53
  • 52 Week High28.35
  • 52 Week High Date06/16/23
  • 52 Week Low10.93
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap822.033M
  • Shares Out63.82M
  • 10 Day Average Volume0.95M
  • Dividend-
  • Dividend Yield-
  • Beta1.09
  • YTD % Change-40.86

KEY STATS

  • Open13.50
  • Day High13.55
  • Day Low12.73
  • Prev Close13.53
  • 52 Week High28.35
  • 52 Week High Date06/16/23
  • 52 Week Low10.93
  • 52 Week Low Date10/25/23
  • Market Cap822.033M
  • Shares Out63.82M
  • 10 Day Average Volume0.95M
  • Dividend-
  • Dividend Yield-
  • Beta1.09
  • YTD % Change-40.86

RATIOS/PROFITABILITY

  • EPS (TTM)-4.50
  • P/E (TTM)-2.86
  • Fwd P/E (NTM)-3.26
  • EBITDA (TTM)-237.312M
  • ROE (TTM)-72.90%
  • Revenue (TTM)287,999.988
  • Gross Margin (TTM)1.79%
  • Net Margin (TTM)-75,737.84%
  • Debt To Equity (MRQ)3.49%

EVENTS

  • Earnings Date08/06/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Viridian Therapeutics Inc

 

Profile

MORE
Viridian Therapeutics, Inc. is a biopharmaceutical company focused on engineering and developing potential medicines for patients with serious and rare diseases. The Company is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. It is focused on...
Tomas Kiselak
Independent Chairman of the Board
Stephen Mahoney
President, Chief Executive Officer, Director
Thomas Beetham
Chief Operating Officer
Seth Harmon
Principal Financial and Accounting Officer
Address
221 CRESCENT STREET, BLDG. 17, SUITE 401
Waltham, MA
02453
United States

Top Peers

SYMBOLLASTCHG%CHG
PRME
Prime Medicine Inc
8.03+0.50+6.64%
ETNB
89Bio Inc
8.95+0.01+0.11%
SPRY
ARS Pharmaceuticals Inc
8.83-0.36-3.92%
LBPH
Longboard Pharmaceuticals Inc
20.40-0.44-2.11%
PLRX
Pliant Therapeutics Inc
14.59-0.53-3.51%